CN114173805A - Prg4治疗癌症的用途 - Google Patents

Prg4治疗癌症的用途 Download PDF

Info

Publication number
CN114173805A
CN114173805A CN202080049571.8A CN202080049571A CN114173805A CN 114173805 A CN114173805 A CN 114173805A CN 202080049571 A CN202080049571 A CN 202080049571A CN 114173805 A CN114173805 A CN 114173805A
Authority
CN
China
Prior art keywords
cancer
prg4
rhprg4
tgf
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080049571.8A
Other languages
English (en)
Chinese (zh)
Inventor
西林·邦尼
阿努西·萨卡尔
丹宁·A·施密特
本杰明·D·苏利文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lubris LLC
Original Assignee
Lubris LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lubris LLC filed Critical Lubris LLC
Publication of CN114173805A publication Critical patent/CN114173805A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202080049571.8A 2019-06-03 2020-06-03 Prg4治疗癌症的用途 Pending CN114173805A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962856514P 2019-06-03 2019-06-03
US62/856,514 2019-06-03
US202063013427P 2020-04-21 2020-04-21
US63/013,427 2020-04-21
PCT/US2020/035841 WO2020247440A1 (en) 2019-06-03 2020-06-03 Use of prg4 to treat cancer

Publications (1)

Publication Number Publication Date
CN114173805A true CN114173805A (zh) 2022-03-11

Family

ID=73652433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080049571.8A Pending CN114173805A (zh) 2019-06-03 2020-06-03 Prg4治疗癌症的用途

Country Status (5)

Country Link
US (1) US20220332839A1 (https=)
EP (1) EP3976085A4 (https=)
JP (1) JP2022534724A (https=)
CN (1) CN114173805A (https=)
WO (1) WO2020247440A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115125207A (zh) * 2022-08-01 2022-09-30 广州顺泰生物医药科技有限公司 一种诱导干细胞体外定向分化的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000022636A1 (it) * 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
KR102763607B1 (ko) * 2021-10-05 2025-02-07 주식회사 인게니움테라퓨틱스 자연살해 세포의 활성 향상용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015060935A1 (en) * 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
EP3074022B1 (en) * 2013-11-26 2022-03-30 Lubris LLC Compositions and methods for inhibiting intercellular interactions
RU2017129880A (ru) * 2015-01-26 2019-03-04 ЛУБРИС ЭлЭлСи Применение prg4 в качестве противовоспалительного средства

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115125207A (zh) * 2022-08-01 2022-09-30 广州顺泰生物医药科技有限公司 一种诱导干细胞体外定向分化的方法

Also Published As

Publication number Publication date
EP3976085A1 (en) 2022-04-06
US20220332839A1 (en) 2022-10-20
WO2020247440A1 (en) 2020-12-10
EP3976085A4 (en) 2023-04-05
JP2022534724A (ja) 2022-08-03

Similar Documents

Publication Publication Date Title
US10577406B2 (en) FKBP-L polypeptides and uses in angiogenesis-mediated disorders
EP2986631B1 (en) Medical use of syndecan-2
WO2020006385A2 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
JP6649941B2 (ja) Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
EP2822573B1 (en) Treatment of cancer
JP2006520326A (ja) 治療薬
CN114173805A (zh) Prg4治疗癌症的用途
US8808693B2 (en) Semaphorin 3C (Sema3C) inhibitor therapeutics, methods, and uses
KR20130107203A (ko) 섬유증의 검출 및 치료
Choi et al. Fc-saxatilin inhibits VEGF-induced permeability by regulating claudin-5 expression in human brain microvascular endothelial cells
US20190270798A1 (en) Methods and compositions for modulaton of transforming growth factor beta-regulated functions
WO2019028343A1 (en) SMALL MOLECULE INHIBITORS OF SLC25A1
JP5990274B2 (ja) 前立腺病態の処置のためのｅｎ２、ｐａｘ２、および／またはｄｅｆｂ１の標的化
US10626397B2 (en) Therapeutic compositions for breast cancer containing protein kinase D1 inhibitor
JP7033072B2 (ja) Ｓｍｏｃ２を標的化する線維症のための治療方法
US20130209476A1 (en) Treatment of inflammatory disorders
EP2843048B1 (en) NOVEL INTEGRIN alpha9beta1 LIGAND AND USES THEREOF
US20150343021A1 (en) Methods for treating cancer using compositions comprising hss1 and/or hsm1
WO2012175481A1 (en) Compositions and methods for treating leukemia
US11879012B2 (en) Method of modulating cell proliferation
Xu et al. Role and Mechanism of circ_UBR4/miR-10a-5p/KLF4 in Regulating Vascular Smooth Muscle Cell Phenotypic Transformation in Cardiac Allograft Vasculopathy
Meghnani RAGE (Receptor for Advanced Glycation End Products) in melanoma progression
Ge Characterization of SMAD3 function in skeletal muscle growth
HK1248247B (en) Tnfrsf14/ hvem proteins and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220311